Araujo FI, Proença FPP, Ferreira CG, Ventilari SC, Rosado de Castro PH, Moreira RD, Fonseca LMB, Souza SAL, Gutfilen B. Use of (99m)Tc-doxorubicin scintigraphy in females with breast cancer: a pilot study.
Br J Radiol 2015;
88:20150268. [PMID:
26111270 DOI:
10.1259/bjr.20150268]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE
Doxorubicin (Eurofarma, São Paulo, Brazil) is an antitumour agent widely used in the treatment of breast cancer and can be used for tumour tracking when labelled with a radionuclide. Here, we present the results obtained with technetium-99m ((99m)Tc)-doxorubicin, using the direct method, to evaluate its uptake in breast cancer.
METHODS
Four females with confirmed breast carcinoma diagnosis and breast image reporting and data system Category 5 on mammography underwent whole-body and thorax single-photon emission CT/CT imaging 1 and 3 h after (99m)Tc-doxorubicin administration.
RESULTS
We observed increased uptake in breast carcinoma lesions and elimination via renal and hepatic pathways.
CONCLUSION
These preliminary results suggest that (99m)Tc-doxorubicin may be a promising radiopharmaceutical for the evaluation of patients with breast cancer. Further studies are ongoing.
ADVANCES IN KNOWLEDGE
To our knowledge, this is the first study to evaluate the use of a directly labelled doxorubicin tracer in humans. (99m)Tc-doxorubicin could provide information on the response of tumours to doxorubicin.
Collapse